Give to Beat Leukemia and Lymphoma
According to the Leukemia and Lymphoma Society,
- $5 pays to send support info to a newly diagnosed leukemia patient
- $25 covers a prescription co-payment for a leukemia patient
- $35 pays for a leukemia patient to travel to a cancer center
- $40 buys a comprehensive info pack for a child with leukemia
- $50 pays for a CT scan for a patient with leukemia or other blood cancers
- $75 covers the cost of tissue typing for a bone marrow donor
- $100 provides a Family Support Program for a cancer patient for 6 months
- $200 provides a Family Support Program for a cancer patient for 1 year
- $500 provides a blood cancer patient with financial assistance for 1 year
The Leukemia & Lymphoma Society, based in White Plains, NY, is the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. For more information, go to www.leukemia-lymphoma.org/
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
